JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation-Reference-Cited by-同舟云学术

JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation

Published:2018-11-23 Issue:4 Volume:33 Page:995-1010
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Czech Julia,Cordua Sabrina,Weinbergerova Barbora,Baumeister Julian,Crepcia Assja,Han Lijuan,Maié Tiago,Costa Ivan G.^ORCID,Denecke Bernd,Maurer Angela,Schubert Claudia,Feldberg Kristina,Gezer Deniz,Brümmendorf Tim H.,Müller-Newen Gerhard,Mayer Jiri,Racil Zdenek,Kubesova Blanka,Knudsen Trine,Sørensen Anders L.,Holmström Morten^ORCID,Kjær Lasse,Skov Vibe,Larsen Thomas Stauffer,Hasselbalch Hans C.,Chatain Nicolas^ORCID,Koschmieder Steffen^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-018-0295-6.pdf

Reference60 articles.

1. Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017;129:667–79.

2. Broseus J, Park JH, Carillo S, Hermouet S, Girodon F. Presence of calreticulin mutations in JAK2-negative polycythemia vera. Blood. 2014;124:3964–6.

3. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–90.

4. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369:2391–405.

5. Araki M, Yang Y, Masubuchi N, Hironaka Y, Takei H, Morishita S, et al. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood. 2016;127:1307–16.

Cited by 45 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature;British Journal of Haematology;2024-06-10

2. Drug Repositioning via Graph Neural Networks: Identifying Novel JAK2 Inhibitors from FDA-Approved Drugs through Molecular Docking and Biological Validation;Molecules;2024-03-19

3. Calreticulin and JAK2V617F driver mutations induce distinct mitotic defects in myeloproliferative neoplasms;Scientific Reports;2024-02-02

4. Modulation of human thrombopoietin receptor conformations uncouples JAK2 V617F-driven activation from cytokine-induced stimulation;Blood;2023-11-23

5. Machine Learning-Based Drug Repositioning of Novel Janus Kinase 2 Inhibitors Utilizing Molecular Docking and Molecular Dynamic Simulation;Journal of Chemical Information and Modeling;2023-10-31